United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $526.96, for a total value of $5,006,120.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $170,968,483.28. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Trading Down 1.5%

Shares of UTHR stock opened at $521.00 on Friday. The company’s 50-day moving average price is $533.74 and its 200-day moving average price is $537.53. The stock has a market cap of $22.35 billion, a price-to-earnings ratio of 18.64, a PEG ratio of 1.79 and a beta of 0.59. United Therapeutics Corporation has a twelve month low of $302.19 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same period last year, the business earned $6.41 earnings per share. United Therapeutics’s revenue was down 1.9% compared to the same quarter last year. As a group, equities research analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on UTHR. JPMorgan Chase & Co. lifted their target price on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Morgan Stanley set a $515.00 price target on United Therapeutics in a report on Thursday, August 6th. Bank of America cut their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $646.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in UTHR. BlackRock Inc. acquired a new stake in shares of United Therapeutics in the second quarter valued at $2,868,735,000. Avoro Capital Advisors LLC boosted its holdings in United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after acquiring an additional 383,838 shares during the period. Wellington Management Group LLP boosted its holdings in United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. AQR Capital Management LLC boosted its holdings in United Therapeutics by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after acquiring an additional 295,221 shares during the period. Finally, Janus Henderson Group PLC grew its position in United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after acquiring an additional 70,829 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.